HTR1B
5-hydroxytryptamine receptor 1B
As of the edition of 20 October 2026, HTR1B (5-hydroxytryptamine receptor 1B, UniProt P28222) has 12 drugs tested at it and 23 companies on the list, 3 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P28222
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Nervous system; Lungs and airways; Cancer; Immune system; Infections; Inherited and neonatal; Injuries; Mental health
- Registered trials of its drugs
- 139
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 8 |
| Went quiet | 3 |
| Stopped | 1 |
| Total | 12 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sumatriptan | Marketed | Phase 4 | none listed |
| Rizatriptan | Marketed | Phase 4 | none listed |
| Zolmitriptan | Marketed | Phase 4 | none listed |
| Eletriptan | Marketed | Phase 4 | none listed |
| Almotriptan | Marketed | Phase 4 | none listed |
| NP-101 | Stopped | Phase 3 | none listed |
| Frovatriptan | Marketed | Phase 4 | none listed |
| Naratriptan | Marketed | Phase 3 | none listed |
| Eltoprazine | Went quiet | Phase 2 | none listed |
| DFN-02 | Went quiet | Phase 3 | none listed |
| Ergoloid | Marketed | Phase 2 | none listed |
| Trelanserin | Went quiet | Phase 2 | none listed |
12 of 12 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 6 |
| Engaged | 2 |
| Undetermined | 12 |
| Total on the list | 23 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Johnson & Johnson | Route B |
| Almirall | Route B |
The other 20 companies at HTR1B
In the product23 companies in all; 20 are not named here, and no score is.
See the 23 companies at HTR1B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.